Periodic fever syndrome are a set of disorders characterized by recurrent episodes of systemic and organ-specific inflammation.
The syndromes are diverse, but tend to cause episodes of fever, joint pains, skin rashes, abdominal pains and may lead to chronic complications such as amyloidosis.
In 2018, the global Periodic Fever Syndrome market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Periodic Fever Syndrome status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Periodic Fever Syndrome development in United States, Europe and China.

The key players covered in this study
Novartis
Simvastatin
Merck
Swedish Orphan Biovitrum
...

Market segment by Type, the product can be split into
Hyperimmunoglobulinemia D Syndrome
Familial Mediterranean Fever
TNF Receptor-Associated Periodic Syndrome
Cryopyrin-Associated Periodic Syndrome
Others

Market segment by Application, split into
Hospitals
Retail Pharmacy

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Periodic Fever Syndrome status, future forecast, growth opportunity, key market and key players.
To present the Periodic Fever Syndrome development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Periodic Fever Syndrome are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.